3.255 -0.205 (-5.92%) | 02-19 15:38 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 4.52 | 1-year : | 5.27 |
Resists | First : | 3.86 | Second : | 4.52 |
Pivot price | 3.33 ![]() |
|||
Supports | First : | 2.92 | Second : | 2.33 |
MAs | MA(5) : | 3.28 ![]() |
MA(20) : | 3.15 ![]() |
MA(100) : | 2.81 ![]() |
MA(250) : | 1.8 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 65.4 ![]() |
D(3) : | 62.5 ![]() |
RSI | RSI(14): 51.8 ![]() |
|||
52-week | High : | 4.48 | Low : | 0.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NXL ] has closed above bottom band by 45.1%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.53 - 3.54 | 3.54 - 3.55 |
Low: | 3.3 - 3.31 | 3.31 - 3.33 |
Close: | 3.44 - 3.46 | 3.46 - 3.49 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Tue, 18 Feb 2025
Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSD - Potential Breakthrough for Veterans - StockTitan
Mon, 10 Feb 2025
Nexalin Technology, Inc. Appointed Industry Co-Chair of National Traumatic Brain Injury Registry Coalition - Nasdaq
Mon, 10 Feb 2025
Nexalin (NXL) Secures Leadership Role in $4.5B Brain Injury Market - Key Details Investors Should See - StockTitan
Tue, 04 Feb 2025
Nexalin technology's chief medical officer buys $2,980 in common stock - MSN
Fri, 24 Jan 2025
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Thu, 23 Jan 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23 - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 0 (M) |
Shares Float | 13 (M) |
Held by Insiders | 1.036e+007 (%) |
Held by Institutions | 19.2 (%) |
Shares Short | 320 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.49e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -6 % |
Return on Assets (ttm) | 962.1 % |
Return on Equity (ttm) | -83.9 % |
Qtrly Rev. Growth | 162080 % |
Gross Profit (p.s.) | 11.59 |
Sales Per Share | -31.83 |
EBITDA (p.s.) | 29988.3 |
Qtrly Earnings Growth | -0.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.11 |
Price to Cash Flow | 36.77 |
Dividend | 0 |
Forward Dividend | 508550 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |